| Improved annotation of the insect vector of citrus greening disease: biocuration by a diverse genomics community S Saha, PS Hosmani, K Villalobos-Ayala, S Miller, T Shippy, M Flores, ... Database 2017, bax032, 2017 | 73 | 2017 |
| Metabolic changes are associated with melphalan resistance in multiple myeloma DC Koomen, MB Meads, DM Magaletti, JD Guingab-Cagmat, PS Oliveira, ... Journal of Proteome Research 20 (6), 3134-3149, 2021 | 12 | 2021 |
| Racial and ethnic differences in clinical outcomes among multiple myeloma patients treated with CAR T therapy LC Peres, LB Oswald, C Dillard, G De Avila, T Nishihori, BJ Blue, ... Blood 140 (Supplement 1), 623-625, 2022 | 11 | 2022 |
| Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma AGM Mostofa, A Distler, MB Meads, E Sahakian, JJ Powers, A Achille, ... JCI insight 6 (24), 2021 | 11 | 2021 |
| IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB–and caspase-8–dependent mechanisms L Zhou, Y Zhang, MB Meads, Y Dai, Y Ning, X Hu, L Li, K Sharma, ... Blood Advances 5 (19), 3776-3788, 2021 | 11 | 2021 |
| Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma DH Lee, A Kumar, T Mohammed, LC Peres, M Alsina, C Bachmeier, ... Blood Advances 7 (16), 4247-4257, 2023 | 8 | 2023 |
| Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: US Myeloma Immunotherapy … H Hashmi, DK Hansen, LC Peres, OC Puglianini, C Freeman, G De Avila, ... Haematologica 109 (5), 1514, 2024 | 6 | 2024 |
| Factors associated with refractoriness or early progression after idecabtagene vicleucel (Ide-cel) in patients with relapsed/refractory multiple myeloma (RRMM): US Myeloma CAR … H Hashmi, DK Hansen, LC Peres, OA Castaneda Puglianini, CL Freeman, ... Blood 140 (Supplement 1), 4642-4645, 2022 | 6 | 2022 |
| High metabolic tumor volume is associated with higher toxicity and decreased efficacy of BCMA CAR-T cell therapy in multiple myeloma R Villanueva, DK Hansen, RP Tonseth, KL Gage, Z Wei, G De Avila, ... Blood 140 (Supplement 1), 10402-10404, 2022 | 4 | 2022 |
| Reinforcement learning to optimize the treatment of multiple myeloma KH Shain, D Hart, AS Silva, R Alugubelli, G De Avila, PR Sudalagunta, ... Blood 134, 5511, 2019 | 4 | 2019 |
| Simple score of albumin and CRP predicts high-grade toxicity in patients with multiple myeloma receiving CAR-T therapy OS Akhtar, K Modi, J Kim, L Skelson, E Smith, MA Al-Jumayli, ... Transplantation and cellular therapy 30 (3), 283. e1-283. e10, 2024 | 3 | 2024 |
| Patient-reported outcomes among multiple myeloma patients treated with standard of care idecabtagene vicleucel LB Oswald, LM Gudenkauf, X Li, G De Avila, LC Peres, K Kirtane, ... Cancers 15 (19), 4711, 2023 | 3 | 2023 |
| Sarcopenia prevalence and influence on the development of toxicity and length of stay in patients with relapsed and refractory myeloma treated with commercial anti-BCMA CART cells N Parker, K Modi, R Villanueva, L Skelson, A Scotto, M Booth-Jones, ... Blood 140 (Supplement 1), 4688-4690, 2022 | 3 | 2022 |
| Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy LC Peres, LB Oswald, CM Dillard, G De Avila, T Nishihori, BJ Blue, ... Blood Advances 8 (1), 251-259, 2024 | 2 | 2024 |
| Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma M Tantawy, G Yang, RR Algubelli, G DeAvila, SM Rubinstein, RF Cornell, ... Frontiers in Cardiovascular Medicine 10, 1181806, 2023 | 2 | 2023 |
| LCL161 interacts synergystically with panobinostat in multiple myeloma cells through non-canonical NF-κB-and caspase-8-dependent mechanisms L Zhou, Y Zhang, MB Meads, Y Dai, Y Ning, X Hu Blood Adv 5 (19), 3776-3788, 2021 | 2 | 2021 |
| Ex vivo drug sensitivity and functional genomics platform identifies novel combinations targeting intrinsic and extrinsic apoptotic signaling pathways in multiple myeloma AS Silva, R Renatino-Canevarolo, MB Meads, MDCS Silva, ... Blood 136, 49-50, 2020 | 2 | 2020 |
| Immune Engager Therapies Are Associated with Better Outcomes in Post Ide-Cel Relapse in MM-an Analysis of the US MM Immunotherapy Consortium Database. M Janakiram, J Khouri, O Castaneda, L Shune, D Dima, G Kaur, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | 1 | 2024 |
| A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel DK Hansen, LC Peres, JA Miranda, K Reid, G De Avila, D Huggar, ... Blood 142, 1004, 2023 | 1 | 2023 |
| Baseline systemic inflammatory markers interleukin 6 and ferritin are associated with toxicities and progression-free survival in multiple myeloma patients treated with … DK Hansen, LC Peres, CL Freeman, OA Castaneda Puglianini, ... Blood 140 (Supplement 1), 12778-12780, 2022 | 1 | 2022 |
